Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7560120 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Sep, 2022
(1 year, 25 days ago) | |
US6960346 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Jul, 2023
(2 months ago) | |
US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(8 years from now) | |
US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(10 years from now) | |
US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(15 years from now) |
Dexycu Kit is owned by Eyepoint Pharms.
Dexycu Kit contains Dexamethasone.
Dexycu Kit has a total of 7 drug patents out of which 2 drug patents have expired.
Expired drug patents of Dexycu Kit are:
Dexycu Kit was authorised for market use on 09 February, 2018.
Dexycu Kit is available in suspension;intraocular dosage forms.
Dexycu Kit can be used as treatment of postoperative inflammation, a method of loading medication into a syringe and delivering the medication to a treatment site.
The generics of Dexycu Kit are possible to be released after 23 June, 2039.
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic